AMO Pharma is led by a team of industry professionals who combine extensive experience in biomedical science and research with proven skill in all phases of drug development and commercialization and a true passion for making a positive difference for patients. With senior leadership based in the U.S. and in the U.K., the company can leverage an international network of contacts and resources in all operational areas, including asset acquisition, collaborative opportunities in drug development, patient advocacy, disease awareness, KOL development and execution of global clinical trials.

Michael Snape, Ph.D. - Chief Executive Officer, Chief Scientific Officer
Michael Snape, Ph.D. - Chief Executive Officer, Chief Scientific Officer

Dr. Snape is a neurobiologist who has spent 27 years in the pharmaceutical industry working for large and emerging biopharmaceutical companies. He has experience founding and funding companies at inception through IPO on the public markets. His principal experience lies in the area of demonstrating clinical proof-of-concept with novel targeted therapeutics in rare diseases. He is named an inventor in numerous patents and is a scientific advisor to several patient foundations. He earned a PhD in neurobiology from London University after study at Maudsley and Bethlem Hospital and holds a faculty position at Case Western University.

Martyn Williams - Chief Financial Officer
Martyn Williams - Chief Financial Officer

Mr. Williams has held senior operational and financial management positions over the last thirty years in international businesses including Cookson Group, RMC Group, Walsh International Inc. and latterly as CEO of Ark Therapeutics plc, a LSE-listed biotech company. He has played key roles in raising a total of 250 million GBP, both publicly and privately and in completing two IPOs - one LSE full listing and one IPO on NASDAQ. He has experience in international M&A transactions, including both acquisitions and divestments, as well as in strategic management of corporate growth and restructuring.

>Joe Horrigan, MD – Chief Medical Officer
Joe Horrigan, MD – Chief Medical Officer

Dr. Horrigan is a pediatric neuropsychiatrist. He has 20 years of experience in the pharmaceutical and biotech industry, both as a clinical investigator and as a sponsor. Dr. Horrigan was a Senior Director in the Neurosciences Medicines Development Center at GlaxoSmithKline, where he also co-founded and led the company-wide Medicines for Children Advisory Network that collaborated with all therapeutic areas in the company. Dr. Horrigan also served as Assistant Vice President and Head of Medical Research for Autism Speaks, the largest science and advocacy organization in the U.S. devoted to autism spectrum disorders (ASD). Most recently, he has served as Vice President of Clinical Development and Medical Affairs for Neuren Pharmaceuticals Limited, leading that company’s clinical development efforts in neurodevelopmental disorders and traumatic brain injury. Dr. Horrigan received his Sc.B. degree from Brown University and his medical degree from the University of Rochester. Dr. Horrigan is also a Clinical Associate Professor at the University of North Carolina.

>Joe Horrigan, MD – Chief Medical Officer
Alison McMorn, PH.D – VP, Clinical Development

Dr. McMorn is an experienced clinical development researcher and has led, planned and managed global clinical development programs for gastro-intestinal/hepatology, pain and psychiatry products. Most recently she served as a Director of Clinical Programs at Shire Pharmaceuticals. She holds an undergraduate degree in Pharmacology and a PhD in psychology from the University of Leeds, UK.